ArticleCommunications medicine2026
Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited insight into the biology of essential thrombocythemia (ET) and polycythemia vera (PV) has constrained therapeutic development. We therefore aimed to prioritize genetically supported molecular determinants underlying disease susceptibility and hematologic phenotypes, and to distinguish shared and subtype-specific regulation.
methodsWe implemented an optimized post-GWAS framework combining omics-wide Bayesian colocalization with Mendelian randomization (MR) to prioritize genetically supported molecular determinants of ET and PV. Colocalization-guided MR analyses were used to infer causal relationships, with additional analyses incorporating other phenotypic traits to support biological interpretation.
resultsHere, we show that higher genetically predicted levels of PARP1, BRAP, ERP29, PPP1CC, and RPN1 are consistently associated with risk of both ET and PV, whereas MYB is specifically associated with ET. Several biomarkers influenced blood cell counts, with BRAP, ERP29, and PPP1CC increasing platelet, red blood cell, and white blood cell counts, while MYB increased platelet production but reduced red and white blood cells. Additionally, MYB promoted BRAP, ERP29, PPP1CC, and EPO signaling while suppressing THPO, whereas MYB gene effects showed opposite patterns on these pathways, blood cell counts, and ET risk. BRAP, PPP1CC, and ERP29 exerted concordant regulatory effects on MPL, RPN1, THPO, and PARP1, except for EPO, which they negatively regulated. Finally, hypermethylation at cg17916418 and cg23511909 suppressed RPN1 expression and increased ET and PV risk, with RPN1 acting as a key mediator.
conclusionsThis study provides a genetics-guided map of shared and subtype-specific molecular features in ET and PV, highlighting potential therapeutic pathways and molecular signals distinguishing the two diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.